POLYMED - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 3.6
| Stock Code | POLYMED | Market Cap | 15,327 Cr. | Current Price | 1,512 ₹ | High / Low | 2,938 ₹ |
| Stock P/E | 44.2 | Book Value | 285 ₹ | Dividend Yield | 0.23 % | ROCE | 18.2 % |
| ROE | 14.2 % | Face Value | 5.00 ₹ | DMA 50 | 1,427 ₹ | DMA 200 | 1,700 ₹ |
| Chg in FII Hold | -3.49 % | Chg in DII Hold | 1.76 % | PAT Qtr | 83.4 Cr. | PAT Prev Qtr | 89.0 Cr. |
| RSI | 60.8 | MACD | 44.1 | Volume | 62,003 | Avg Vol 1Wk | 1,26,268 |
| Low price | 1,182 ₹ | High price | 2,938 ₹ | PEG Ratio | 1.43 | Debt to equity | 0.08 |
| 52w Index | 18.8 % | Qtr Profit Var | -2.04 % | EPS | 33.8 ₹ | Industry PE | 38.8 |
Chart Patterns & Moving Averages: POLYMED is trading above its 50 DMA (₹1,427) but below its 200 DMA (₹1,700), showing short-term strength but medium-term weakness. Price action indicates support near ₹1,480–₹1,500 and resistance around ₹1,650–₹1,680.
RSI & Momentum: RSI at 60.8 reflects moderately strong momentum. MACD at 44.1 is bullish, confirming upward bias.
Bollinger Bands: Price is near the upper band, suggesting momentum continuation but risk of short-term pullback.
Volume Trends: Current volume (62K) is below average (126K), showing reduced participation and limiting breakout conviction.
Entry/Exit Zones:
- **Entry:** ₹1,480–₹1,500 (near support zone)
- **Exit:** ₹1,650–₹1,680 (resistance zone)
- **Stop-loss:** ₹1,460 (below support)
Trend Status: Consolidation with bullish bias; short-term momentum improving but medium-term weakness persists below 200 DMA.
Positive
- Strong ROCE (18.2%) and ROE (14.2%).
- EPS at ₹33.8 supports earnings visibility.
- PEG ratio at 1.43 indicates fair growth-adjusted valuation.
- Debt-to-equity ratio low (0.08), showing balance sheet stability.
- DII holding increased (+1.76%).
Limitation
- Price below 200 DMA reflects medium-term weakness.
- PAT declined sequentially (₹89 Cr → ₹83.4 Cr).
- FII holding decreased (-3.49%).
- Dividend yield modest (0.23%).
- Volume below average, limiting breakout conviction.
Company Negative News
- Sequential profit decline.
- Reduced FII participation.
- Valuation slightly above industry PE (44.2 vs 38.8).
Company Positive News
- DII inflows show domestic institutional confidence.
- EPS remains strong despite profit decline.
- Price recovery from 52-week low (₹1,182).
- MACD bullish, supporting short-term momentum.
Industry
- Industry PE at 38.8, lower than POLYMED’s valuation.
- Pharma/medical devices sector supported by global demand.
- Competitive peers with similar fundamentals but lower valuations.
Conclusion
POLYMED is in a short-term uptrend with moderate momentum and strong fundamentals, though medium-term weakness persists below the 200 DMA. Entry near ₹1,480–₹1,500 offers upside toward ₹1,650–₹1,680, with strict stop-loss discipline at ₹1,460. Suitable for swing trades with risk-managed setups; long-term investors should remain cautious due to stretched valuations.
This HTML report captures POLYMED’s short-term bullish momentum but highlights medium-term weakness and valuation risks. Would you like me to add a sector overlay comparing POLYMED with peers like Polycap, Tarsons, and Transasia Biomedicals to benchmark relative strength and valuation positioning?